By Drug Target Review2025-08-14T09:00:00
Engineered cell therapies are offering a potential new way to treat lupus – not by suppressing symptoms, but by reprogramming the immune system itself. For the first time, lasting remission looks like a real possibility.
Already a member? Sign in
By highlighting cutting-edge research and its practical applications, Drug Target Review enables readers to make decisions that accelerate innovation, translate discoveries into therapies, and create tangible benefits for patients worldwide.
By becoming a member you join a connected and collaborative community driving the industry forward. Member benefits include:
2026-03-31T14:05:00Z
2026-03-30T09:54:00Z
2024-05-10T11:23:31
Sponsored by BellBrook Labs
2023-03-08T16:29:20
Sponsored by Bio-Techne
2023-03-30T09:15:30
Sponsored by Halo Labs
2024-02-08T11:07:39
Sponsored by Samplix ApS
2025-04-02T14:00:00
Sponsored by Eurofins Discovery
2023-09-27T13:56:39
Sponsored by Euretos
Site powered by Webvision Cloud